MA45469A - Acides nucléiques de bêta-caténine et leurs utilisations - Google Patents
Acides nucléiques de bêta-caténine et leurs utilisationsInfo
- Publication number
- MA45469A MA45469A MA045469A MA45469A MA45469A MA 45469 A MA45469 A MA 45469A MA 045469 A MA045469 A MA 045469A MA 45469 A MA45469 A MA 45469A MA 45469 A MA45469 A MA 45469A
- Authority
- MA
- Morocco
- Prior art keywords
- beta
- nucleic acids
- catenin nucleic
- catenin
- acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317123P | 2016-04-01 | 2016-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45469A true MA45469A (fr) | 2019-02-06 |
Family
ID=59965299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045469A MA45469A (fr) | 2016-04-01 | Acides nucléiques de bêta-caténine et leurs utilisations |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10844385B2 (fr) |
| EP (1) | EP3436582B1 (fr) |
| MA (1) | MA45469A (fr) |
| WO (1) | WO2017173297A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45469A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques de bêta-caténine et leurs utilisations |
| WO2023122317A2 (fr) * | 2021-12-23 | 2023-06-29 | Aligos Therapeutics, Inc. | MOLÉCULES D'ACIDE NUCLÉIQUE INTERFÉRENT COURT (SINA) POUR CIBLER LA β-CATÉNINE ET LEURS UTILISATIONS |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0216860B1 (fr) | 1985-03-15 | 1992-10-28 | SUMMERTON, James | Polymeres stereoreguliers de liaison a un polynucleotide |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| ES2061416T3 (es) | 1990-10-12 | 1997-03-01 | Max Planck Gesellschaft | Ribozimas modificadas. |
| DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5716824A (en) | 1995-04-20 | 1998-02-10 | Ribozyme Pharmaceuticals, Inc. | 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes) |
| US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
| CA2253382A1 (fr) | 1996-01-16 | 1997-07-24 | Ribozyme Pharmaceuticals, Inc. | Synthese de methoxy nucleosides et de molecules d'acide nucleique enzymatique |
| US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
| JP2003525017A (ja) * | 1998-04-20 | 2003-08-26 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | 遺伝子発現を調節しうる新規な化学組成を有する核酸分子 |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| CA2328356A1 (fr) | 1999-12-22 | 2001-06-22 | Itty Atcravi | Vehicules recreatifs |
| US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| BRPI0117338B1 (pt) | 2000-03-30 | 2016-06-21 | Massachusetts Inst Technology | método para produzir células animais nocauteadas in vitro e método para produzir uma célula nocauteada |
| EP1309726B2 (fr) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Mediateurs d'interference arn specifiques de sequences arn |
| US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| DE10133858A1 (de) | 2001-07-12 | 2003-02-06 | Aventis Pharma Gmbh | Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression |
| US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| US20040023220A1 (en) | 2002-07-23 | 2004-02-05 | Lawrence Greenfield | Integrated method for PCR cleanup and oligonucleotide removal |
| US7923547B2 (en) | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| ATE485394T1 (de) | 2003-06-02 | 2010-11-15 | Univ Massachusetts | Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai |
| US7750144B2 (en) | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
| CA2528012C (fr) | 2003-06-02 | 2015-11-24 | University Of Massachusetts | Procedes et compositions de commande de l'efficacite permettant de rendre silencieux un arn |
| DK3604537T3 (da) | 2003-06-13 | 2022-02-28 | Alnylam Europe Ag | Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme |
| EP2514758B2 (fr) | 2004-03-15 | 2021-06-23 | City of Hope | Procédés et compositions pour l'inhibition spécifique de l'expression génique par l'ARN double brin |
| EP1765847A4 (fr) | 2004-05-27 | 2010-10-20 | Alnylam Pharmaceuticals Inc | Acide ribonucleique double brin resistant aux nucleases |
| WO2008109369A2 (fr) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Composés d'acide nucléique permettant d'inhiber l'expression de gène tnf et utilisations de ceux-ci |
| DK2195428T3 (en) | 2007-09-19 | 2014-03-03 | Applied Biosystems Llc | SIRNA SEQUENCE-INDEPENDENT MODIFICATION FORMS TO REDUCE TARGET-FAILING PHENOTYPIC EFFECTS OF RNAI, AND STABILIZED FORMS THEREOF |
| US20110065774A1 (en) | 2008-01-31 | 2011-03-17 | Alnylam Pharmaceuticals | Chemically modified oligonucleotides and uses thereof |
| JP5697993B2 (ja) | 2008-02-11 | 2015-04-08 | アールエックスアイ ファーマシューティカルズ コーポレーション | 修飾ＲＮＡｉポリヌクレオチドおよびその使用 |
| WO2010028054A1 (fr) | 2008-09-02 | 2010-03-11 | Alnylam Europe Ag. | Compositions et procédés d'inhibition de l'expression d'un gène egfr mutant |
| JP2012502991A (ja) | 2008-09-22 | 2012-02-02 | アールエックスアイ ファーマシューティカルズ コーポレーション | 皮膚適用におけるｒｎａ干渉 |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| CA2760774A1 (fr) | 2009-05-05 | 2010-11-11 | Altermune Technologies, Llc | Immunite chimiquement programmable |
| EP2504435B1 (fr) * | 2009-11-26 | 2019-11-13 | Quark Pharmaceuticals, Inc. | Composés d'arnsi comportant des substitutions terminales |
| EP3587579B1 (fr) | 2010-07-06 | 2021-03-03 | Dicerna Pharmaceuticals, Inc. | Procédés et compositions pour l'inhibition spécifique de bêta-caténine par arn double brin |
| CA2805265A1 (fr) * | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Inhibition a mediation par interference arn de catenine (proteine associee a cadherine), expression du gene beta 1 (ctnnb1) a l'aide de petit acide nucleique interferent (sian) |
| WO2013012758A1 (fr) | 2011-07-19 | 2013-01-24 | Ontorii, Inc. | Procédés pour la synthèse d'acides nucléiques fonctionnalisés |
| JP2015502931A (ja) | 2011-11-18 | 2015-01-29 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 修飾ＲＮＡｉ剤 |
| AR090905A1 (es) * | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| EP2844261B1 (fr) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | Compositions de petit acide nucléique interférent (sina) |
| SG11201500232UA (en) | 2012-07-13 | 2015-04-29 | Wave Life Sciences Pte Ltd | Chiral control |
| PL2978845T3 (pl) | 2013-03-27 | 2020-11-16 | Isarna Therapeutics Gmbh | Zmodyfikowane oligonukleotydy tgf-beta |
| WO2014169049A1 (fr) | 2013-04-09 | 2014-10-16 | Duke University | Arn 2'fluoro-modifiés en tant qu'immunostimulateurs |
| WO2015069587A2 (fr) | 2013-11-06 | 2015-05-14 | Merck Sharp & Dohme Corp. | Conjugués contenant des peptides pour double distribution moléculaire d'oligonucléotides |
| ES2917473T3 (es) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| US10988764B2 (en) | 2014-06-23 | 2021-04-27 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via RNA interference |
| IL316808A (en) | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| MA45469A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques de bêta-caténine et leurs utilisations |
-
0
- MA MA045469A patent/MA45469A/fr unknown
-
2017
- 2017-03-31 US US15/476,341 patent/US10844385B2/en active Active
- 2017-03-31 EP EP17776789.4A patent/EP3436582B1/fr active Active
- 2017-03-31 WO PCT/US2017/025424 patent/WO2017173297A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3436582A1 (fr) | 2019-02-06 |
| US10844385B2 (en) | 2020-11-24 |
| EP3436582B1 (fr) | 2021-10-13 |
| EP3436582A4 (fr) | 2020-02-12 |
| US20170314030A1 (en) | 2017-11-02 |
| WO2017173297A1 (fr) | 2017-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1020I1 (fr) | Anticorps thérapeutiques et leurs utilisations | |
| IL272463A (en) | Nucleic acid molecules and uses thereof | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| EP3661965A4 (fr) | Anticorps anti-cd47 et leurs utilisations | |
| EP3504243A4 (fr) | Anticorps anti-tim-3 et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3426288A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
| MA46471A (fr) | Protéines actriib à variant et leurs utilisations | |
| EP3283516A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3481430A4 (fr) | Conjugués de type acide nucléique et leurs utilisations | |
| EP3328895A4 (fr) | Anticorps anti-pd-l1 et leurs utilisations | |
| EP3334706A4 (fr) | Pillararènes et utilisations de ceux-ci | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| EP3383904A4 (fr) | Anticorps ctla-4 et leurs utilisations | |
| EP3349802A4 (fr) | Dendrimères lipocationiques et leurs utilisations | |
| EP3538261A4 (fr) | Catalyseurs en pérovskite et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| EP3341007A4 (fr) | Inhibiteurs de malt1 et leurs utilisations | |
| EP3347021A4 (fr) | Cyano-thiénotriazoloazépines et leurs utilisations | |
| EP3347020A4 (fr) | Acétamide thiénotriazoldiazépines et leurs utilisations | |
| EP3436585A4 (fr) | Acides nucléiques kras et leurs utilisations | |
| MA46945A (fr) | Exopolysaccharides et leurs utilisations | |
| EP3377897A4 (fr) | Biocapteurs de lactate et leurs utilisations | |
| MA46562A (fr) | Anticorps anti-chikv et leurs utilisations |